Diabetes and prostate cancer risk in the REDUCE trial

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 4, 2011, Pages 326-331

  Wu, C ^a,b   Moreira, D M ^b,c   Gerber, L ^b,d   Rittmaster, R S ^e   Andriole, G L ^f,g   Freedland, S J ^b,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BARNES JEWISH HOSPITAL   (United States)

Author keywords

diabetes; obesity; PSA; REDUCE

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CANCER GRADING; CANCER RISK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RISK;

EID: 80955165946     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.28     Document Type: Article

References (35)

1. Wynder EL, Mabuchi K, Whitmore Jr WF. Epidemiology of cancer of the prostate. Cancer 1971; 28: 344-360.
2. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 1071-1078. (Pubitemid 38918167)
3. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-2062. (Pubitemid 44877026)
4. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998; 9: 3-9. (Pubitemid 28048654)
5. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW et al. Obesity, diabetes, and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-1983. (Pubitemid 44664277)
6. Calton BA, Chang SC, Wright ME, Kipnis V, Lawson K, Thompson FE et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007; 18: 493-503. (Pubitemid 46684823)
7. Velicer CM, Dublin S, White E. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 2007; 10: 46-51. (Pubitemid 46358910)
8. Darbinian JA, Ferrara AM, Van Den Eeden SK, Quesenberry Jr CP, Fireman B, Habel LA. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 628-635. (Pubitemid 351469213)
9. Baradaran N, Ahmadi H, Salem S, Lotfi M, Jahani Y, Mehrsai AR et al. The protective effect of diabetes mellitus against prostate cancer: role of sex hormones. Prostate 2009; 69: 1744-1750.
10. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the Health Professionals Follow-up Study. Int J Cancer 2009; 124: 1398-1403.
11. Turner EL, Lane JA, Donovan JL, Davis MJ, Metcalfe C, Neal DE et al. Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate Testing for Cancer and Treatment Study). Int J Cancer 2011; 128: 440-446.
12. Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, Nagai M et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control 2010; 21: 1025-1032.
13. Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T et al. Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 2008; 31: 930-931.
14. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men 2001-2002. Am J Epidemiol 2006; 164: 978-983. (Pubitemid 44729839)
15. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275-2280. (Pubitemid 350146217)
16. Culp S, Porter M. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. BJU Int 2009; 104: 1457-1461.
17. Hekal IA, Ibrahiem EI. Obesity-PSA relationship: a new formula. Prostate Cancer Prostatic Dis 2010; 13: 186-190.
18. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-1202.
19. Jayachandran J, Aronson WJ, Terris MK, Presti Jr JC, Amling CL, Kane CJ et al. Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the Shared Equal-Access Regional Cancer Hospital database. Cancer Epidemiol Biomarkers Prev 2010; 19: 9-17.
20. Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009; 101: 1272-1279.
21. Hammarsten J, Högstedt B. Clinical, haemodynamic, anthropo-metric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004; 13: 47-55. (Pubitemid 38455847)
22. Hammarsten J, Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887-2895. (Pubitemid 41713128)
23. Muller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H. Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev 2009; 18: 1350-1356.
24. Stocks T, Lukanova A, Rinaldi S, Biessy C, Dossus L, Lindahl B et al. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 2007; 120: 2678-2686. (Pubitemid 46651291)
25. Abdollah F, Briganti A, Suardi N, Gallina A, Capitanio U, Salonia A et al. Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? Prostate Cancer Prostatic Dis 2011; 14: 74-78.
26. Hong SK, Lee ST, Kim SS, Min KE, Byun SS, Cho SY et al. Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer. Prostate 2009; 69: 820-826.
27. Kim HS, Presti Jr JC, Aronson WJ, Terris MK, Kane CJ, Amling CL et al. Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate 2010; 70: 1540-1546.
28. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353. (Pubitemid 38529873)
29. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001; 85: 991-996. (Pubitemid 33016002)
30. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92: 1910-1917. (Pubitemid 32036921)
31. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myo-cardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004; 57: 1096-1103. (Pubitemid 39446649)
32. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, 2011.
33. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006; 29: 1263-1268. (Pubitemid 44125920)
34. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305. (Pubitemid 40813563)
35. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009; 20: 1617-1622.